Previous Next


№4' 2016


International Medical Journal, Vol. 22., Iss. 4, 2016, P. 67−72.


Yavorska V. O., Bondar O. B., Skoryi A. Yu., Krasnorudska T. V., Volodarska N. M., Afanasiev D. H.

Kharkiv Medical Academy of Postgraduate Education
Kharkiv City Clinical Hospital № 7, Ukraine

Asthenic syndrome is a common state at chronic cerebral ischemia (dyscirculatory encephalopathy) especially at its initial manifestations. Ninety patients were investigated to evaluate and compare the effect of alpha−lipoic acid (Espa−lipon, Esparma) in ampoules and tablets on the dynamics of clinical changes in asthenic syndrome at chronic cerebral ischemia. The efficacy and safety of its application as antioxidant, metabolic neuroprotector in patients with chronic cerebral ischemia was confirmed. The state of cognitive functions was tested using Mini−study of mental status (MMSE) and Montreal scale on admission (visit 1), on day 10 (visit 2), day 30 (visit 3), day 60 (visit 4). Asthenic symptoms were evaluated using a subjective rating scale of fatigue (MFI−20), test ZAZZO−ZCT. Side effects of the drug were determined during the whole period of observation. Complex therapy with the alpha−lipoic acid was well tolerated by all patients. After the treatment, positive changes were noted in the cognitive status of the patients. The obtained findings indicate high performance, good tolerance and prolonged therapeutic effect of alpha−lipoic acid. The effectiveness of the drug in ampoules and tablets was similar at administration for 30 days. Administration of alpha−lipoic acid is fairly safe and is not accompanied by severe side effects.

Key words: cognitive functions, asthenic syndrome, chronic disorders of cerebral circulation, alpha−lipoic acid.

Go on Top